A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

Summary

Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis.

This observational study is to evaluate the safety and efficacy of fluzoparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment, and preliminarily evaluate the pharmacoeconomic of fluzoparib in the treatment of ovarian cancer.

Conditions

• Ovarian Cancer

Interventions

DRUG

fluzoparib monotherapy or combination therapy

patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy

Sponsors & Collaborators

• First Hospital of China Medical University

  collaborator OTHER

• Cancer Hospital of Xinjiang Medical University

  collaborator UNKNOWN

• First Affiliated Hospital Xi'an Jiaotong University

  collaborator OTHER

• Qingyuan People's Hospital

  collaborator OTHER

• Zhejiang University

  collaborator OTHER

• Panzhihua Central Hospital

  collaborator OTHER

• Liangshan First People's Hospital

  collaborator UNKNOWN

• Guang'an People's Hospital

  collaborator UNKNOWN

• Affiliated Hospital of North Sichuan Medical College

  collaborator OTHER

• Cancer Hospital of Guizhou Province

  collaborator OTHER

• Guizhou International General Hospital

  collaborator UNKNOWN

• Yichang Central People's Hospital

  collaborator OTHER

• Wuhan Fourth Hospital

  collaborator UNKNOWN

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Tongji Hospital

  lead OTHER

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-01-14

Primary Completion

2026-12-31

Completion

2032-12-31

Countries

• China

Study Locations